secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2026-06-01T20:04:33+00:00
Accession:  0001339970-26-000036
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma posts investor presentation highlighting efzofitimod for pulmonary sarcoidosis
--------------------------------------------------------------------------------

- Presentation covers efzofitimod (tRNA synthetase biologic) in pulmonary sarcoidosis and pipeline beyond.
- No specific clinical data or financial guidance disclosed in the excerpt provided.
- Company presented at investor conferences using these materials; full content not detailed in filing excerpt.
- aTyr focuses on tRNA synthetase biology; efzofitimod is their lead candidate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000133997026000036/0001339970-26-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000133997026000036/atyr-20260601.htm
  HTML page:      https://secwatch.observer/filing/0001339970-26-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer